Tuberculosis (TB), despite being a preventable and curable disease, continues to be a significant global health issue. The key to successful TB control lies in early detection and prompt treatment. This article provides an overview of the recent advancements in TB detection methods.
The GeneXpert MTB/RIF assay, a fully automated nucleic acid amplification test, has revolutionized TB detection. It simultaneously detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampicin within two hours. This rapid, sensitive, and specific test has significantly improved the diagnostic landscape, especially in settings with high HIV prevalence.
Line Probe Assays (LPAs) are WHO-endorsed tests that detect MTBC and resistance to rifampicin and isoniazid. LPAs are faster than conventional drug susceptibility testing methods and have been instrumental in the early detection of multidrug-resistant TB (MDR-TB) cases.
Next-Generation Sequencing (NGS) is a powerful tool that provides comprehensive information about the TB genome. It can identify drug resistance mutations, track transmission patterns, and offer insights into the evolution and adaptation of the TB bacterium. Although currently limited by cost and technical requirements, NGS holds great potential for TB diagnosis and research.
Immunological tests, such as interferon-gamma release assays (IGRAs), have made strides in diagnosing latent TB infection. These tests measure the immune response to TB antigens and are more specific than the traditional tuberculin skin test.
With the advent of advanced diagnostic methods, the fight against TB has entered a new phase. These technologies offer enhanced sensitivity, specificity, and speed, enabling faster detection and treatment initiation. However, accessibility and affordability remain challenges in resource-limited settings. Continued research and investment are crucial to make these advanced diagnostic tools universally available and to ultimately eradicate TB.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation